Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceGlobeNewsWire • 03/27/24
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsGlobeNewsWire • 03/25/24
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial HypertensionGlobeNewsWire • 11/20/23
Aerovate Therapeutics Announces Third Quarter Financial Results and Business HighlightsGlobeNewsWire • 11/13/23
Aerovate Therapeutics Announces Second Quarter Financial Results and Business HighlightsGlobeNewsWire • 08/14/23
Aerovate: Smart Investment Opportunity With This Developer Of Inhaled Imatinib For PAHSeeking Alpha • 06/28/23
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International ConferenceGlobeNewsWire • 05/22/23
Aerovate Therapeutics Announces First Quarter Financial Results and Business HighlightsGlobeNewsWire • 05/15/23
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business HighlightsGlobeNewsWire • 03/29/23
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open ResearchGlobeNewsWire • 11/17/22
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022GlobeNewsWire • 10/18/22
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)GlobeNewsWire • 05/16/22
Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial HypertensionGlobeNewsWire • 12/15/21